Public Release:  Time for balance? Preventing atypical femoral fractures related to bisphosphonates

Two recent articles in JBJS publications examine the relationship between bisphosphonates and atypical femoral fractures

Journal of Bone and Joint Surgery

Needham, MA - Physicians worldwide frequently prescribe bisphosphonates such as alendronate (Fosamax) and ibandronate (Boniva) to treat osteoporosis and prevent fragility fractures. Unfortunately, long-term bisphosphonate use has been linked to an increased risk of atypical femoral fractures. In the March 3, 2015 edition of JBJS Reviews, Blood et al. offer some guidance on how to prevent such fractures.

The authors note that prodromal thigh pain and a radiolucent line on X-rays of patients with a history of chronic bisphosphonate use are strong indicators of an impending fracture. Among bisphosphonate users who have an incomplete fracture with little or no pain, the authors recommend a trial of bisphosphonate discontinuation, protected weight-bearing, calcium and vitamin-D supplementation, and possible teriparatide (Forteo) therapy. They add that prophylactic fixation should be considered if there is no radiographic or symptomatic improvement after two to three months of that conservative approach. Blood et al. further recommend that patients at high risk for atypical femoral fracture should consider discontinuing bisphosphonate therapy after five years of continuous use. They also encourage orthopaedists to assess the contralateral femur for signs of impending fracture in patients who have already had an atypical femoral fracture.

JBJS Reviews Editor, Thomas A. Einhorn, MD, points out "It is important to note that while the majority of these fractures are most likely associated with bisphosphonate use, recent findings show they may also occur in patients on other anti-resorptive drugs such as denosumab (Prolia) and a very small number of patients have developed these bone changes and fractures with no history of drug use."

The recommendations by Blood et al. notwithstanding, the absolute risk of atypical femoral fractures is low (3.2 to 50 cases per 100,000 person-years among short-term bisphosphonate users and about 100 cases per 100,000 person-years among long-term users). Consequently, for most people with osteoporosis, the proven fragility-fracture risk-reduction benefits of bisphosphonates outweigh the risks of atypical femoral fracture, as discussed by JBJS Editor-in-Chief Marc Swiontkowski, MD, in the January 28, 2015 "Case Connections" article published in JBJS Case Connector.

###

Disclosure: None of the authors received payments or services, either directly or indirectly (i.e., via his or her institution), from a third party in support of any aspect of this work. One or more of the authors, or his or her institution, has had a financial relationship, in the thirty-six months prior to submission of this work, with an entity in the biomedical arena that could be perceived to influence or have the potential to influence what is written in this work. No author has had any other relationships, or has engaged in any other activities, that could be perceived to influence or have the potential to influence what is written in this work. Complete Disclosures of Potential Conflicts of Interest available.

About JBJS Reviews

JBJS Reviews is a new orthopaedic review journal recently launched by JBJS, Inc. JBJS Reviews is published online, enabling continuous publication, optimization for mobile access, and integrated continuing medical education (CME) opportunities. The Editor of JBJS Reviews is Thomas A. Einhorn, MD.

About JBJS Case Connector

JBJS Case Connector is an online journal that includes thousands of orthopaedic case reports. It compiles symptoms, conditions, and demographic details to empower surgeons to find cases similar to theirs and to mine the database to reveal emerging trends and identify patterns, distinguishing between truly rare cases and repeated, related single instances of a larger problem. JBJS Case Connector is co-edited by Marc F. Swiontkowski, MD, and Thomas W. Bauer, MD, PhD.

About JBJS, Inc.

JBJS, Inc., is a not-for-profit publisher specializing in orthopaedic information. It publishes The Journal of Bone & Joint Surgery, which has been the most valued source of information for orthopaedic surgeons and researchers for 125 years. Other publications include JBJS Case Connector and JBJS Essential Surgical Techniques, along with CME and professional development products. Twitter: @jbjs.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.